article

1. Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities..  The Lancet. Rheumatology.  2024
2. Understanding the multiple dimensions of ageing: 5Ms for the rheumatologist..  The Lancet. Rheumatology.  2024
3. A pilot trial of integrating the Patient-Reported Outcome Measurement Information System (PROMIS®) into rheumatology care..  Clinical and experimental rheumatology.  2024
4. Frailty and its association with readmissions in patients with rheumatoid arthritis: A national readmissions database study..  Clinical rheumatology.  2024
5. Inflammation and aging-related disease: A transdisciplinary inflammaging framework..  GeroScience.  2024
6. Association Between Frailty Status and Readmissions in Hospitalized Patients With Systemic Lupus Erythematosus..  ACR open rheumatology.  6:700-706. 2024
7. Prevalence and Factors Associated with De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis: A Medicare Claims-Based Observational Study..  Drugs & aging.  41:601-613. 2024
8. Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted-Synthetic Disease-Modifying Antirheumatic Drugs..  Arthritis care & research.  76:627-635. 2024
9. Deprescribing medications among patients with multiple prescribers: A socioecological model..  Journal of the American Geriatrics Society.  72:660-669. 2023
10. Initiation of Disease-Modifying Antirheumatic Drugs in Older Medicare Beneficiaries With New Diagnosis of Late-Onset Rheumatoid Arthritis..  ACR open rheumatology.  5:694-700. 2023
11. Optimizing Medication Use in Older Adults With Rheumatic Musculoskeletal Diseases: Deprescribing as an Approach When Less May Be More..  ACR open rheumatology.  4:1031-1041. 2022
12. Modeling success: How to work effectively with your biostatistician..  Journal of the American Geriatrics Society.  70:2449-2454. 2022
13. Provider Specialty and the Use of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Older Adults in the 2005-2016 National Ambulatory Medical Care Survey..  ACR open rheumatology.  4:332-337. 2022
14. Access and Cost-Related Nonadherence to Prescription Medications Among Lupus Patients and Controls: The Michigan Lupus Epidemiology and Surveillance Program..  Arthritis care & research.  73:1561-1567. 2021
15. Medicare beneficiary panel characteristics associated with high Part D biologic disease-modifying anti-rheumatic drug prescribing for older adults among rheumatologists..  Medicine.  100:-. 2021
16. Persistently Frequent Emergency Department Utilization Among Persons With Systemic Lupus Erythematosus..  Arthritis care & research.  71:1410-1418. 2019
17. Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus - Michigan Lupus Epidemiology and Surveillance Program, 2014-2015..  MMWR. Morbidity and mortality weekly report.  68:819-824. 2019
18. Opioid dispensation among systemic lupus erythematosus patients who persistently frequent the emergency department..  Journal of opioid management.  16:23-31. 2019
19. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system..  Journal of infection and public health.  7:50-3. 2013
20. The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities..  American journal of infection control.  40:760-5. 2012